OTTAWA, ONTARIO--(Marketwired - June 18, 2015) - Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public pre-hearing conference in the matter of the price of the patented medicine Soliris and Alexion Pharmaceuticals Inc., the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada. The pre-hearing conference will take place from 9:30 a.m. to 5:00 p.m. (EST) on Monday, June 22; Tuesday, June 23; and Wednesday, June 24, 2015 at the following location:
Patented Medicine Prices Review Board |
Hearing Room #1 |
333 Laurier Avenue West, 18th floor |
Ottawa, Ontario K1P 1C1 |
The purpose of the pre-hearing conference is to allow parties to identify or circumscribe the issues related to the hearing and resolve any other issues that may facilitate the conduct of the hearing.
Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria-a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells-and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.
Quick Facts
Related Products
Statement of Allegations of Board Staff
Additional Links
Status of Ongoing Proceedings (Patented Medicine Prices Review Board)
Compendium of Policies, Guidelines and Procedures (Patented Medicine Prices Review Board)
Contact Information: